Clinical features and prognostic outcomes of angioimmunoblastic T cell lymphoma in an Asian multicenter study

References

• Lunning MA, Vose JM. Angioimmunoblastic T-cell lymphoma: the many-faced lymphoma. Blood. 2017;129(9):1095–1102. doi:10.1182/blood-2016-09-692541
   PubMed Web of Science ®Google Scholar
• Federico M, Rudiger T, Bellei M, et al. Clinicopathologic characteristics of angioimmunoblastic T-cell lymphoma: analysis of the international peripheral T-cell lymphoma project. J Clin Oncol. 2013;31(2):240–246. doi:10.1200/JCO.2011.37.3647
   PubMed Web of Science ®Google Scholar
• Mourad N, Mounier N, Brière J, et al. Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d’Etude des Lymphomes de l’Adulte (GELA) trials. Blood. 2008;111(9):4463–4470. doi:10.1182/blood-2007-08-105759
   PubMed Web of Science ®Google Scholar
• Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375–2390. doi:10.1182/blood-2016-01-643569
   PubMed Web of Science ®Google Scholar
• Xie Y, Jaffe ES. How I diagnose angioimmunoblastic T-cell lymphoma. Am J Clin Pathol. 2021;156(1):1–14. doi:10.1093/ajcp/aqab090
   PubMed Web of Science ®Google Scholar
• Quintanilla-Martinez L, Fend F, Moguel LR, et al. Peripheral T cell lymphoma with Reed-Sternberg-like cells of B-cell phenotype and genotype associated with Epstein-Barr virus infection. Am J Surg Pathol. 1999;23(10):1233–1240. doi:10.1097/00000478-199910000-00008
   PubMed Web of Science ®Google Scholar
• Lee S-S, Rüdiger T, Odenwald T, et al. Angioimmunoblastic T cell lymphoma is derived from mature T-helper cells with varying expression and loss of detectable CD4. Int J Cancer. 2003;103(1):12–20. doi:10.1002/ijc.10758
   PubMed Web of Science ®Google Scholar
• Attygalle A, Al-Jehani R, Diss TC, et al. Neoplastic T cells in angioimmunoblastic T-cell lymphoma express CD10. Blood. 2002;99(2):627–633. doi:10.1182/blood.v99.2.627
   PubMed Web of Science ®Google Scholar
• Dupuis J, Boye K, Martin N, et al. Expression of CXCL13 by neoplastic cells in angioimmunoblastic T-cell lymphoma (AITL): a new diagnostic marker providing evidence that AITL derives from follicular helper T cells. Am J Surg Pathol. 2006;30(4):490–494. doi:10.1097/00000478-200604000-00009
   PubMed Web of Science ®Google Scholar
• Dorfman DM, Brown JA, Shahsafaei A, et al. Programmed death-1 (PD-1) is a marker of germinal center-associated T cells and angioimmunoblastic T-cell lymphoma. Am J Surg Pathol. 2006;30(7):802–810. doi:10.1097/01.pas.0000209855.28282.ce
   PubMed Web of Science ®Google Scholar
• Grogg KL, Attygalle AD, Macon WR, et al. Angioimmunoblastic T-cell lymphoma: a neoplasm of germinal-center T-helper cells? Blood. 2005;106(4):1501–1502. doi:10.1182/blood-2005-03-1083
   PubMed Web of Science ®Google Scholar
• Roncador G, Garcia Verdes-Montenegro JF, Tedoldi S, et al. Expression of two markers of germinal center T cells (SAP and PD-1) in angioimmunoblastic T-cell lymphoma. Hematologica. 2007;92(8):1059–1066. doi:10.3324/haematol.10864
   PubMed Web of Science ®Google Scholar
• Bisig B, Thielen C, Herens C, et al. c-Maf expression in angioimmunoblastic T-cell lymphoma reflects follicular helper T-cell derivation rather than oncogenesis. Histopathology. 2012;60(2):371–376. doi:10.1111/j.1365-2559.2011.04022.x
   PubMed Web of Science ®Google Scholar
• Gaulard P, de Leval L. Follicular helper T cells: implications in neoplastic hematopathology. Semin Diagn Pathol. 2011;28(3):202–213. doi:10.1053/j.semdp.2011.03.003
   PubMed Web of Science ®Google Scholar
• Vose J, Armitage J, Weisenburger D. International T-Cell Lymphoma Project. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008;26(25):4124–4130.
   PubMed Web of Science ®Google Scholar
• de Leval L, Parrens M, Le Bras F, et al. Angioimmunoblastic T-cell lymphoma is the most common T-cell lymphoma in two distinct French information data sets. Haematologica. 2015;100(9):e361-4–e364. doi:10.3324/haematol.2015.126300
   PubMed Web of Science ®Google Scholar
• Tokunaga T, Shimada K, Yamamoto K, et al. Retrospective analysis of prognostic factors for angioimmunoblastic T-cell lymphoma: a multicenter cooperative study in Japan. Blood. 2012;119(12):2837–2843. doi:10.1182/blood-2011-08-374371
   PubMed Web of Science ®Google Scholar
• Advani RH, Skrypets T, Civallero M, et al. Outcomes and prognostic factors in angioimmunoblastic T-cell lymphoma: final report from the international T-cell project. Blood. 2021;138(3):213–220. doi:10.1182/blood.2020010387
   PubMed Web of Science ®Google Scholar
• International Non-Hodgkin’s Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin’s lymphoma. N Engl J Med. 1993;329(14):987–994.
   PubMed Web of Science ®Google Scholar
• Gallamini A, Stelitano C, Calvi R, et al. Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood. 2004;103(7):2474–2479. doi:10.1182/blood-2003-09-3080
   PubMed Web of Science ®Google Scholar
• Iqbal J, Wright G, Wang C, et al. Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma. Blood. 2014;123(19):2915–2923. doi:10.1182/blood-2013-11-536359
   PubMed Web of Science ®Google Scholar
• Dahmani A, Delisle JS. TGF-β in T cell biology: implications for cancer immunotherapy. Cancers (Basel). 2018;10(6):194. doi:10.3390/cancers10060194
   PubMed Web of Science ®Google Scholar
• Colak S, Ten Dijke P. Targeting TGF-β signaling in cancer. Trends Cancer. 2017;3(1):56–71. doi:10.1016/j.trecan.2016.11.008
   PubMed Web of Science ®Google Scholar
• Castro F, Cardoso AP, Gonçalves RM, et al. Interferon-gamma at the crossroads of tumor immune surveillance or evasion. Front Immunol. 2018;9:847. doi:10.3389/fimmu.2018.00847
   PubMed Web of Science ®Google Scholar
• Kumar V, Vashishta M, Kong L, et al. The role of notch, hedgehog, and wnt signaling pathways in the resistance of tumors to anticancer therapies. Front Cell Dev Biol. 2021;9:650772. doi:10.3389/fcell.2021.650772
   PubMed Web of Science ®Google Scholar
• Moskowitz AJ. Practical treatment approach for angioimmunoblastic T-cell lymphoma. J Oncol Pract. 2019;15(3):137–143. doi:10.1200/JOP.18.00511
   PubMed Web of Science ®Google Scholar
• Ohmoto A, Fuji S. Cyclosporine for angioimmunoblastic T-cell lymphoma: a literature review. Expert Rev Hematol. 2019;12(11):975–981. doi:10.1080/17474086.2019.1652590
   PubMed Web of Science ®Google Scholar
• Dogan A, Ngu LS, Ng SH, et al. Pathology and clinical features of angioimmunoblastic T-cell lymphoma after successful treatment with thalidomide. Leukemia. 2005;19(5):873–875. doi:10.1038/sj.leu.2403710
   PubMed Web of Science ®Google Scholar
• Chan TS, Tse E, Kwong YL. Chidamide in the treatment of peripheral T-cell lymphoma. Oncol Targets Ther. 2017;10:347–352. doi:10.2147/OTT.S93528
   PubMed Web of Science ®Google Scholar
• Attygalle AD, Kyriakou C, Dupuis J, et al. Histologic evolution of angioimmunoblastic T-cell lymphoma in consecutive biopsies: clinical correlation and insights into natural history and disease progression. Am J Surg Pathol. 2007;31(7):1077–1088. doi:10.1097/PAS.0b013e31802d68e9
   PubMed Web of Science ®Google Scholar
• Horwitz S, O’Connor OA, Pro B, et al. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. Lancet. 2019;393(10168):229–240. doi:10.1016/S0140-6736(18)32984-2
   PubMed Web of Science ®Google Scholar